Additionally, the company reiterated its willingness to “identifying an appropriate and comprehensive resolution of the overall opioid litigation.” At the same time, it remains ready to defend its actions.
Furthermore, Johnson & Johnson stated that its products, Duragesic, Nucynta and Nucynta ER accounted less than one percent of total prescriptions in the United States. It was responsible in marketing the products. In 2015, it sold its marketing rights for Nucynta and since 2008 it stopped marketing Duragesic in the United States.
In August, a district court judge in Oklahoma ordered Johnson & Johnson to pay $527 million to the state. Judge Thad Balkman found that the company “engaged in in false and misleading marketing of both their drugs and opioids generally… have caused exponentially increasing rates of addiction, overdose deaths and Neonatal Abstinence Syndrome.”
The company appealed the ruling.